Fig. 6

Persistency chart (proportional hazards model) for octreotide vs lanreotide, patients with 180-day washout period (n = 663). Survival indicates probability of patients continuing treatment. Hazard ratio (risk of discontinuing treatment) for octreotide vs lanreotide: 1.381; p = 0.011